Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
News|Articles|July 27, 2026
Dosing begins in phase 2a/2b trial of YB-101 after Yarrow Bioscience closes merger with VYNE Therapeutics
Author(s)Lynda Charters
A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.
Advertisement
Advertisement
Yarrow Bioscience announced in a press release that it closed its merger with VYNE Therapeutics and dosing of patients began in a phase 2a/b trial (NCT07682896) of
Related to this article
The nonprescription 0.125% apraclonidine drop is approved for adults and children 12 years and older, and Alcon says each dose whitens the eye for up to 12 hours.
Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year-end 2026.
Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.
Himani Goyal, MD, John J. Chen, MD, PhD, and Mark P. Breazzano, MD, FACS, point to academic compensation, optic nerve damage, and who chooses retina.
Advertisement
Advertisement